Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

21. Multiple sclerosis

Multiple sclerosis Autosynthesis - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button

Trip Evidence Maps2018

24. Preapproval and postapproval evidence on drugs for multiple sclerosis

Preapproval and postapproval evidence on drugs for multiple sclerosis 29695598 2018 05 22 1526-632X 90 21 2018 May 22 Neurology Neurology Preapproval and postapproval evidence on drugs for multiple sclerosis. 964-973 10.1212/WNL.0000000000005561 To review the evidence supporting the European Union marketing authorization of drugs for multiple sclerosis (MS) and assess how far postmarketing research addresses information gaps at the time of approval. Through its database, we identified drugs (...) approved by the European Medicines Agency and gathered data on pivotal trials from the European Public Assessment Reports and corresponding publications. We searched Medline, Embase, Cochrane Library, and trial registries for postmarketing randomized controlled trials testing the drugs identified in any form of the disease. Since approval of interferon and glatiramer up to 2017, the Agency has examined 10 drugs for the treatment of MS, and 8 were included in this study: alemtuzumab, daclizumab

EvidenceUpdates2018

25. A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis

A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis 29582713 2018 05 23 1477-0873 32 6 2018 Jun Clinical rehabilitation Clin Rehabil A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis. 713-721 10.1177/0269215517745348 This study is aimed at providing a quantitative evaluation (...) on different therapies of spasticity caused by multiple sclerosis. PubMed and Embase database. We searched for randomized controlled trials that met the requirements. Percentages of improved patients' spasticity scale, mild adverse effect and severe adverse effect were extracted as outcomes. The forest plots accompanied with surface under the cumulative ranking curves were used to reveal the efficacy and safety of these therapies. In all, 23 randomized controlled trials with a total of 2720 patients were

EvidenceUpdates2018

26. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology 29686116 2018 04 24 1526-632X 90 17 2018 Apr 24 Neurology Neurology Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee (...) of the American Academy of Neurology. 777-788 10.1212/WNL.0000000000005347 To develop recommendations for disease-modifying therapy (DMT) for multiple sclerosis (MS). A multidisciplinary panel developed DMT recommendations, integrating findings from a systematic review; followed an Institute of Medicine-compliant process to ensure transparency and patient engagement; and developed modified Delphi consensus-based recommendations concerning starting, switching, and stopping DMTs pertinent to people

EvidenceUpdates2018

27. Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology 29686117 2018 04 24 1526-632X 90 17 2018 Apr 24 Neurology Neurology Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American (...) Academy of Neurology. 789-800 10.1212/WNL.0000000000005345 To review evidence on starting, switching, and stopping disease-modifying therapies (DMTs) for multiple sclerosis (MS) in clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and progressive MS forms. Relevant, peer-reviewed research articles, systematic reviews, and abstracts were identified (MEDLINE, CENTRAL, EMBASE searched from inception to November 2016). Studies were rated using the therapeutic classification scheme. Prior

EvidenceUpdates2018

28. Teriflunomide (Aubagio) - relapsing remitting multiple sclerosis (RRMS)

Teriflunomide (Aubagio) - relapsing remitting multiple sclerosis (RRMS) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent activity SBDs written for approved after September 1

Health Canada - Drug and Health Product Register2018

29. Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis

Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis 29549193 2018 03 17 1468-330X 2018 Mar 16 Journal of neurology, neurosurgery, and psychiatry J. Neurol. Neurosurg. Psychiatry Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis. jnnp-2017-317463 10.1136/jnnp-2017-317463 Fatigue is a major disabling symptom in many chronic diseases including multiple sclerosis (MS), but treatment options are limited.Here, we (...) tested the effectiveness of a self-guided , interactive, online fatigue management programme (ELEVIDA) based on principles of cognitive behavioural therapy (CBT) and related psychotherapeutic approaches (eg, mindfulness) for reducing fatigue in MS. Patients with MS and self-reported fatigue were recruited via the website of the German MS Society and assigned via an automated randomisation generator (1:1, no blocking or stratification) to a 12-week online intervention (ELEVIDA, n=139, 82% female, mean

EvidenceUpdates2018

30. Multiple sclerosis.

Multiple sclerosis. Multiple sclerosis continues to be a challenging and disabling condition but there is now greater understanding of the underlying genetic and environmental factors that drive the condition, including low vitamin D levels, cigarette smoking, and obesity. Early and accurate diagnosis is crucial and is supported by diagnostic criteria, incorporating imaging and spinal fluid abnormalities for those presenting with a clinically isolated syndrome. Importantly (...) , there is an extensive therapeutic armamentarium, both oral and by infusion, for those with the relapsing remitting form of the disease. Careful consideration is required when choosing the correct treatment, balancing the side-effect profile with efficacy and escalating as clinically appropriate. This move towards more personalised medicine is supported by a clinical guideline published in 2018. Finally, a comprehensive management programme is strongly recommended for all patients with multiple sclerosis, enhancing

Lancet2018

31. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. BACKGROUND: No treatment has consistently shown efficacy in slowing disability progression in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of siponimod, a selective sphingosine 1-phosphate (S1P) receptor 1,5 modulator, on disability progression in patients with SPMS. METHODS: This event-driven and exposure-driven, double-blind, phase (...) 3 trial was done at 292 hospital clinics and specialised multiple sclerosis centres in 31 countries. Using interactive response technology to assign numbers linked to treatment arms, patients (age 18-60 years) with SPMS and an Expanded Disability Status Scale score of 3·0-6·5 were randomly assigned (2:1) to once daily oral siponimod 2 mg or placebo for up to 3 years or until the occurrence of a prespecified number of confirmed disability progression (CDP) events. The primary endpoint was time

Lancet2018

32. Exploring cued and non-cued motor imagery interventions in people with multiple sclerosis: a randomised feasibility trial and reliability study

Exploring cued and non-cued motor imagery interventions in people with multiple sclerosis: a randomised feasibility trial and reliability study Exploring cued and non-cued motor imagery interventions in people with multiple sclerosis: a randomised feasibility trial and reliability study | Archives of Physiotherapy | Full Text Advertisement Menu Search Search all BMC articles Search Menu Table of Contents , Raija Kuisma , Angela Glynn and Thomas Berger Archives of Physiotherapy 2018 8 :6 (...) © The Author(s). 2018 Received: 29 June 2017 Accepted: 31 January 2018 Published: 2 March 2018 Background Motor imagery (MI) is increasingly used in neurorehabilitation to facilitate motor performance. Our previous study results demonstrated significantly improved walking after rhythmic-cued MI in people with multiple sclerosis (pwMS). The present feasibility study was aimed to obtain preliminary information of changes in walking, fatigue, quality of life (QoL) and MI ability following cued and non-cued MI

Archives of physiotherapy2018 Full Text: Link to full Text with Trip Pro

33. Evidenced-Based Cognitive Rehabilitation for Persons With Multiple Sclerosis: An Updated Review of the Literature From 2007 to 2016

Evidenced-Based Cognitive Rehabilitation for Persons With Multiple Sclerosis: An Updated Review of the Literature From 2007 to 2016 28958607 2018 02 08 1532-821X 99 2 2018 Feb Archives of physical medicine and rehabilitation Arch Phys Med Rehabil Evidenced-Based Cognitive Rehabilitation for Persons With Multiple Sclerosis: An Updated Review of the Literature From 2007 to 2016. 390-407 S0003-9993(17)31117-6 10.1016/j.apmr.2017.07.021 To update the clinical recommendations for cognitive (...) rehabilitation of people with multiple sclerosis (MS), based on a systematic review of the literature from 2007 through 2016. Searches of MEDLINE, PsycINFO, and CINAHL were conducted with a combination of the following terms: attention, awareness, cognition, cognitive, communication, executive, executive function, language, learning, memory, perception, problem solving, reasoning, rehabilitation, remediation, training, processing speed, and working memory. One hundred twenty-nine articles were identified

EvidenceUpdates2018

34. Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS)

Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS) 29386274 2018 02 28 1526-632X 90 9 2018 Feb 27 Neurology Neurology Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS). e797-e807 10.1212/WNL.0000000000005013 To determine whether a multifaceted vestibular-related rehabilitation program (Balance and Eye-Movement Exercises for Persons with Multiple Sclerosis; BEEMS) improves balance in persons with MS and whether (...) total (-7.6, -14.0 to -1.33, p = 0.02) scores. BEEMS improved multiple outcomes regardless of whether brainstem/cerebellar lesions were present, supporting the generalizability of BEEMS for ambulatory people with MS who have at least minimally impaired balance and fatigue. NCT01698086. This study provides Class I evidence that BEEMS training improves dynamic posturography-based balance, dizziness, fatigue, and quality of life in persons with MS. © 2018 American Academy of Neurology. Hebert Jeffrey R

EvidenceUpdates2018

35. Randomized Controlled Trial to Examine the Impact of Aquatic Exercise Training on Functional Capacity, Balance, and Perceptions of Fatigue in Female Patients With Multiple Sclerosis

Randomized Controlled Trial to Examine the Impact of Aquatic Exercise Training on Functional Capacity, Balance, and Perceptions of Fatigue in Female Patients With Multiple Sclerosis 28735720 2018 02 08 1532-821X 99 2 2018 Feb Archives of physical medicine and rehabilitation Arch Phys Med Rehabil Randomized Controlled Trial to Examine the Impact of Aquatic Exercise Training on Functional Capacity, Balance, and Perceptions of Fatigue in Female Patients With Multiple Sclerosis. 234-241 S0003-9993 (...) (17)30471-9 10.1016/j.apmr.2017.06.015 To assess the effects of an 8-week aquatic exercise training program on functional capacity, balance, and perceptions of fatigue in women with multiple sclerosis (MS). Randomized controlled design. Referral center of an MS society. Women (N=32; mean age ± SD, 36.4±8.2y) with diagnosed relapsing-remitting MS. After undergoing baseline testing by a neurologist, participants were allocated to either an intervention (aquatic training program, n=17) or a control

EvidenceUpdates2018

36. EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders

EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders European Medicines Agency - News and Events - EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders Search for medicines Main navigation News and press releases EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders Press release 02/03/2018 EMA urgently reviewing multiple sclerosis (...) medicine Zinbryta following cases of inflammatory brain disorders Medicine to be voluntarily withdrawn from the market by the company The European Medicines Agency (EMA) has started an urgent review of the multiple sclerosis medicine Zinbryta (daclizumab) following 7 cases of serious inflammatory brain disorders in Germany, including encephalitis and meningoencephalitis, and one case in Spain. In parallel to the start of the review, the company that markets Zinbryta (Biogen Idec Ltd) has informed EMA

European Medicines Agency - EPARs2018

37. EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta

EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta European Medicines Agency - News and Events - EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta Search for medicines Main navigation News and press releases EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta Press release 07/03/2018 EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta Evidence indicates (...) risk of serious inflammatory brain disorders The European Medicines Agency (EMA) has recommended the immediate suspension and recall of the multiple sclerosis medicine Zinbryta (daclizumab beta) following 12 reports of serious inflammatory brain disorders worldwide, including encephalitis and meningoencephalitis. Three of the cases were fatal. A preliminary review of the available evidence indicates that immune reactions observed in the reported cases may be linked to the use of Zinbryta. Zinbryta

European Medicines Agency - EPARs2018

38. Cladribine (Mavenclad) - treatment of adult patients with highly active relapsing multiple sclerosis (MS)

Cladribine (Mavenclad) - treatment of adult patients with highly active relapsing multiple sclerosis (MS)

Scottish Medicines Consortium2018

39. Diagnosis and Treatment of Multiple Sclerosis: Guidelines

Diagnosis and Treatment of Multiple Sclerosis: Guidelines Diagnosis and Treatment of Multiple Sclerosis: Guidelines | CADTH.ca Find the information you need Diagnosis and Treatment of Multiple Sclerosis: Guidelines Diagnosis and Treatment of Multiple Sclerosis: Guidelines Published on: January 3, 2018 Project Number: RA0941-000 Product Line: Research Type: Other Diagnostics Report Type: Reference List Result type: Report Question What are the evidence-based guidelines for the full spectrum (...) of care (including diagnosis and treatment) of patients with multiple sclerosis? Key Message One evidence-based guideline was identified regarding the full spectrum of care (including diagnosis and treatment) of patients with multiple sclerosis. Tags multiple sclerosis, nervous system Files Rapid Response Reference List Published : January 3, 2018 Follow us: © 2018 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

Canadian Agency for Drugs and Technologies in Health - Rapid Review2018

40. Multiple sclerosis

Multiple sclerosis Multiple sclerosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Multiple sclerosis Last reviewed: August 2018 Last updated: May 2018 Important updates MS drug daclizumab withdrawn worldwide because of safety concerns Daclizumab, an immunomodulatory drug used in the treatment of relapsing forms of multiple sclerosis, has been removed from the worldwide market due to mounting concerns over its (...) events being reported, characterising the evolving benefit/risk profile of daclizumab will not be possible going forward given the limited number of patients being treated.” 2017 revisions to the McDonald diagnostic criteria for multiple sclerosis The 2017 McDonald criteria include the following changes: In patients with a typical clinically isolated syndrome and clinical or MRI demonstration of dissemination in space, the presence of CSF-specific oligoclonal bands allows a diagnosis

BMJ Best Practice2018